PRISYM ID exhibits at Clinical Trial Supply Europe 2018
PRISYM ID, leading provider of labelling solutions for the clinical trial, medical device and life sciences industries, is a sponsor and exhibitor at the Clinical Trial Supply Europe conference in 2018. The event takes place on the 22-24 January and will be held at the Hurlingham Club, London UK. PRISYM ID will be exhibiting at stand 14.
In planning the 2018 Clinical Trial Supply Forum, the organsers spoke with over 50 clinical trial supply experts from big and small pharmaceutical companies as well as from solution providers. They all said the same thing! You can’t have the best clinical trial supply chain without concrete, end to end planning. In recognition of this fact, CTS 2018 will look in-depth at where the gaps are within your clinical trial supply chain, and offer new solutions on how to fill them. Through interactive roundtables, SWOT analysis and a variety of panel discussions, you will be able to benchmark you CTS planning and take home new strategies in optimising your clinical trial supply chain.
In designing an effective on demand supply chain, it is the clinical trial labeling that can present the most challenges; for these, PRISYM ID provides a sophisticated technology solution which was designed in collaboration with PACT (Project Authoring for Clinical Trials) group and aims to help the clinical trials industry meet the strictest compliance requirements and regulations. The platform allows customers to create a fully integrated approach across the whole label lifecycle, transforming labelling production and processes.
Steve Ellison, PRISYM ID, comments: “Clinical Trials are becoming an increasingly global, competitive and complex environment, in which technology has an ever-greater role to play. We look forward to discussing with peers and industry experts how innovations in labelling and packaging software can help address some of these key topical issues, including patient engagement and retention; local language labelling and compliance.”